Home > Healthcare > Biotechnology > Biopharma > gene therapy market
Get a free sample of Gene Therapy Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Gene Therapy Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Some key trends in the market includes advancements in gene editing technologies, increasing number of clinical trials, and expansion of gene therapies into rare diseases. The development and refinement of gene editing technologies, such as CRISPR-Cas9, zinc finger nucleases (ZFNs), and TALENs, have revolutionized the field of gene therapy. These technologies enable precise and targeted modifications to the genetic material, opening up new possibilities for treating genetic disorders and other diseases.
The non-viral vector segment accounted for a sizable revenue share in 2022 and is estimated to grow significantly through 2032 as non-viral vectors are less likely to trigger immune responses and are associated with lower toxicity, which makes them suitable for clinical use.
Global market for gene therapy was worth USD 9 billion in 2023 and is projected to record growth at 19.4% CAGR from 2024 to 2032 owing to the expansion and development of advanced medicines and gene delivery technologies.
The top players engaged in the global market are Merck KGaA, REGENXBIO, Inc., Oxford BioMedica plc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetic Technologies Corporation, F. Hoffmann-La Roche Ltd, bluebird bio, Inc., Novartis AG, Orchard Therapeutics, Gilead Lifesciences, Inc., BENITEC BIOPHARMA, Sibiono GeneTech Co., Ltd, and Shanghai Sunway Biotech Co., Ltd.
The North America market is set to grow at a rate of 19.2% over 2023-2032 attributed to the strong financial and government support, availability of advanced healthcare infrastructure, and robust R&D ecosystem.